News | July 03, 2025
WuXi XDC announces mechanical completion of Singapore site
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Subscribe To Our Newsletter & Stay Updated
